Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced that senior management will participate in the following investor conferences in October.
Nusano, Inc. has appointed pharmaceutical executive Alexandre Gibim as the company’s Chief Operations Officer (COO). Gibim will be responsible for enabling and scaling Nusano’s business functions to create a reliable domestic and global supply of medical radioisotopes, the active pharmaceutical ingredients (APIs) at the core of next-generation cancer therapeutics.
Video Replay: Unlocking the Next $20-30B Market Opportunity in Oncology: Radioisotope Production & Applications
With many now expecting radiopharamaceuticals to grow into a $20-30 billion market, investors are increasingly looking...
Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, is participating in two conferences in July 2023.
ICR: ‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer
News from the United Kingdom's Institute of Cancer Research (ICR) published in The Lancet Oncology reports that...
Experts at the Dana-Farber Cancer Institute report patient treatments were delayed by three months due to low supply of 177Lu-PSMA-617.
The Welsh Government is working to secure a stable supply of medical radioisotopes for United Kingdom citizens for decades to come.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates